Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05724693 · ClinicalTrials.gov registry record · Phase 1
Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function
A Phase 1 study of Healthy Volunteer and Hepatic Impairment, sponsored by Atea Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT05724693: Completed Phase 1 study of Healthy Volunteer and Hepatic Impairment, sponsored by Atea Pharmaceuticals.
NCT05724693 is a Phase 1 study of Healthy Volunteer and Hepatic Impairment that has completed, run by Atea Pharmaceuticals. The registered enrollment target is 39 participants, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05724693, a Phase 1 study of Healthy Volunteer and Hepatic Impairment, has completed, sponsored by Atea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
To Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Bemnifosbuvir After a Single Dose
Conditions Studied
Interventions
- DRUG Bemnifosbuvir (BEM)
Study Locations (1)
Florida
- Atea Study Site Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2024-04-23 |
| Phase | Phase 1 |
What the finished NCT05724693 record still lists
NCT05724693 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Healthy Volunteer appearing as the primary indexed condition, and to 1 intervention - of which Bemnifosbuvir (BEM) is the first listed.
NCT05724693 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05724693 about?
NCT05724693 is a clinical study titled "Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function". To Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Bemnifosbuvir After a Single Dose
What is the current status of trial NCT05724693?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2023-01-30. Estimated completion is 2024-04-23.
What conditions does trial NCT05724693 study?
This clinical trial studies the following conditions: Healthy Volunteer, Hepatic Impairment.
What interventions are being tested in trial NCT05724693?
The interventions under investigation include: Bemnifosbuvir (BEM) (DRUG).
Who is sponsoring clinical trial NCT05724693?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05724693 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05724693's enrollment target sits among peer trials
39 70th of 112 higher than 43 of 112 other Healthy Volunteer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Volunteer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Healthy Volunteer Study
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors
RECRUITING · Phase 1
-
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
RECRUITING · Phase 1
-
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI